A linear accelerator is commonly used in external beam radiation treatments for patients with cancer. Linear accelerator customizes high energy x-rays or electrons depending on a tumor’s shape and destroys cancer cells, while sparing surrounding normal tissue. It is designed with build-up safety features to ensure that it will not deliver a higher dose than prescribed. The linear accelerator is used to treat all parts or organs of the body, by delivering high-energy x-rays or electrons to the region of the patient’s tumor. A radiation oncologist prescribes the appropriate treatment volume and dosage of radiation. Furthermore, medical physicist and the dosimetrist determine how to deliver the prescribed dose and calculate the amount of time it will take the accelerator to deliver that dose. Then, radiation therapists operate the linear accelerator and give patients their daily radiation treatments.
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/1855
Increasing number of initiatives by various government and private organizations in early diagnosis of cancer, increases the survival rate, and reduces cancer mortality rate, and this is expected to help to boost market growth of linear accelerators for radiation market. For instance, in February 2017, World Health Organization (WHO) proposed new guidelines to improve survival rate of people living with cancer, by ensuring that health service providers can focus on diagnosing and treating the disease earlier. WHO proposed three steps to early diagnosis, which include improve public awareness of different cancer symptoms, investments in strengthening and equipping health services and training, and ensuring people living with cancer can access safe and effective treatment. Moreover, Cancer Research UK organized Early Diagnosis Research Conference in February 2017, to share and discuss latest developments in early diagnosis research.
Growth of the linear accelerators for radiation market size is driven by increasing prevalence and incidence of various types of cancer, coupled with growing patient awareness programs by government and private organizations, and rising adoption of radiotherapy in cancer treatment. For instance, according to the Cancer Atlas: 2017, around 14.1 million new cancer cases were reported in 2012. Moreover, India, China, and other East and Central Asian countries accounted for nearly half of world’s new cancer cases and deaths, in 2017. Furthermore, according to the same source, by 2025, it is expected to increase to 19.3 million new cancer cases and 11.4 million cancer deaths in emerging economies.
According to data findings by the World Health Organization (WHO), in February 2018, cancer is the second-leading cause of death globally, accounting for 8.8 million deaths in 2015. Moreover, the number of new cases of cancer is expected to rise by 70% in the near future, globally, according to the same source. According to the International Agency for Research on Cancer (IARC), in 2012, around 14.1 million new cancer cases were reported. Among these, the most common form of cancer was lung cancer (13%), breast cancer (11.9%), and colorectal cancer (9.7%), globally.
According to the World Cancer Research Fund (WCRF) International, 2015 data findings, 58% of the lung cancer cases were reported in the emerging economies, in 2014. Hungary had the highest rate of lung cancer, followed by Serbia, and North Korea. Moreover, highest incidence of lung cancer was registered in North America and Europe, for the same year. Moreover, according to the Cancer Research UK, 2015 statistics, 55,122 new cases of breast cancer were registered in 2015, U.K. In the U.K., breast cancer was the most common cancer, accounting for 15% of all new cancer cases in 2015. Furthermore, in 2014, 7% cases of breast cancer were registered among the total cancer deaths in the U.K., according to the same source.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/1855
Major concerns of affordability and accessibility for the treatment, lack of trained personnel to operate linear accelerators, are some of the limiting factors, which are expected to hinder the market growth for linear accelerators for radiation.
On the basis of region, global linear accelerators for radiation market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Growing adoption of linear accelerators by prominent cancer treatment centers, worldwide; and upgrading the conventional treatment, will augment growth of the linear accelerators for radiation market, in the near future. In May 2016, Leeds Cancer Centre, a leading providers of cancer care in the U.K. updated its existing treatment equipment with eight Elekta Versa HD linear accelerators. The Versa HD linear accelerators combined with Volumetric Arc Therapy (VMAT) allows to deliver complex head and neck cancer therapy up to 42% faster. Furthermore, in November 2017, Romanian government signed for five Elekta linear accelerators, to supply the country with sophisticated radiation therapy devices. In addition, Princess Margaret Cancer Centre from Canada and Odense University Hospital from Denmark in December 2016, also ordered high-field MR-supported linear accelerator (MR-linac). Both Versa HD linear accelerator and high-field MR-supported linear accelerator (MR-linac) are manufactured by Elekta AB.
Some of the key players operating in the linear accelerators for radiation market include Elekta AB, Siemens Healthcare, Varian Medical Systems, Inc., Accuray Incorporated, Shinva Medical Instrument Co., Ltd., and among others.
Key players in this market are focused on collaborations and sharing their expertise in the radiation therapy to offer comprehensive and effective solution to patients with cancer. For instance, in June 2013, Siemens Healthcare and Varian Medical Systems successfully developed and deployed a software interface that connects Varian’s ARIA oncology information system with Siemens’ ONCOR and PRIMUS accelerators and imaging systems. In September 2017, Elekta and Brainlab entered into a collaboration to integrate use of Elekta’s Versa HD linear accelerator and Brainlab’s ExacTrac patient positioning and monitoring technology.
Reasons to Purchase this Report
• To gain an in-depth understanding of Linear Accelerators for Radiation market globally
• To identify the on-going trends and anticipated growth in the next nine years
• To help industry consultants, Linear Accelerators for Radiation market other stakeholders align their market-centric strategies
• To obtain research-based business decisions and add weight to presentations and marketing strategies
• To gain competitive knowledge of leading market players
Buy This Complete A Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/insight/buy-now/1855
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837